01—Abstract
Summary
Summary of the 10-K filed February 10, 2026. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Exelixis, we, our or us) reported 2025 as its ninth consecutive year of annual profitability, with total revenues of $2,320.1 milliona, up from $2,168.7 million in 2024, and net income of $782.6 million, or $2.78 per diluted share, compared with $521.3 million, or $1.76 per diluted share, in 2024.
Net product revenues rose to $2,122.8 millionb, driven by CABOMETYX, which generated $2,113.4 million, with the filing citing a 16% increase in CABOMETYX units sold, largely from first-line RCC use with nivolumab and previously treated advanced NET. Collaboration revenues fell to $197.3 million from $359.3 million, reflecting lower license revenue from the absence of the large 2024 Ipsen sales milestone. The company ended 2025 with $1.66 billion in cash, cash equivalents and marketable securities, versus $1.75 billion a year earlier, after returning cash through share repurchases.
It repurchased 30.2 million shares for $1,159.7 millionc under its repurchase programs, and $590.2 million remained available under the October 2025 program, which runs through December 31, 2026. Operating cash flow was $884.3 million. Research and development expense declined to $825.0 million from $910.4 million, while management projects R&D expense may increase in 2026 due to zanzalintinib, XB628, XB371 and XB010 trials.
The main forward-looking catalysts are zanzalintinib, for which an NDA with atezolizumab in previously treated metastatic colorectal cancer was accepted with a PDUFA target action date of December 3, 2026, and STELLAR-304 top-line results expected in mid-2026. Investors face material risks from generic cabozantinib competition: multiple ANDA and 505(b)(2) filers have Paragraph IV challenges to CABOMETYX patents, with a consolidated trial scheduled for November 2, 2026, and the composition-of-matter patent with term extension expires in August 2026. The company also faces U.S. drug pricing policy and 340B Program litigation risks.
02—Key points
Key Highlights
- Total revenues of $2,320.1 million in 2025, up from $2,168.7 million in 2024; net product revenues of $2,122.8 million, with CABOMETYX at $2,113.4 million.
- Net income of $782.6 million, or $2.78 per diluted share, versus $521.3 million, or $1.76 per diluted share, in 2024; the filing describes 2025 as the ninth consecutive year of annual profitability.
- Collaboration revenues declined to $197.3 million from $359.3 million, with license revenues of $214.4 million versus $349.2 million, reflecting lower milestone recognition.
- Repurchased 30.2 million shares for $1,159.7 million under repurchase programs; approximately $590.2 million remains available under the October 2025 program through December 31, 2026.
- Zanzalintinib NDA with atezolizumab for previously treated metastatic CRC accepted with standard review and a PDUFA target action date of December 3, 2026; STELLAR-304 top-line results expected mid-2026.
- Generic cabozantinib challenges pending: MSN, Azurity and Handa filings against CABOMETYX patents, with Sun settled in December 2025 and a consolidated trial scheduled for November 2, 2026; the composition-of-matter patent expires August 2026.
- Cash, cash equivalents and marketable securities of $1.66 billion at year-end 2025, versus $1.75 billion a year earlier, with operating cash flow of $884.3 million.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2026, Exelixis kept $0.34.
- Revenue$2.32B100.0%
- Cost of revenue−$83.7M3.6%
- Gross profit$2.24B96.4%
- Operating costs−$1.36B58.8%
- Operating income$872.2M37.6%
- Interest, other & tax−$89.6M3.9%
- Net income$782.6M33.7%
Where FY2026 revenue went
$2.32B- R&D: $825.0M, 36% of revenue
- Net income: $782.6M, 34% of revenue
- SG&A: $518.7M, 22% of revenue
- Cost of revenue: $83.7M, 3.6% of revenue
- Other operating costs: $20.5M, 0.9% of revenue
- Interest, other & tax: $89.6M, 3.9% of revenue
Kept 34% as net incomeOther operating costs $20.5M · 0.9%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2026filed February 10, 2026Financial Statements
FY2026 against FY2025
| Line item | FY2026FY2025 | Change |
|---|---|---|
| Revenue | $2.32B$2.17B | +7.0% |
| Cost of Revenue | $83.70M$76.22M | +9.8% |
| Gross Profit | $2.24B$2.09B | +6.9% |
| R&D Expenses | $825.00M$910.41M | −9.4% |
| SG&A Expenses | $518.73M$492.13M | +5.4% |
| Operating Expenses | $1.45B$1.56B | −7.4% |
| Operating Income | $872.19M$604.62M | +44.3% |
| Net Income | $782.60M$521.30M | +50.1% |
| EPS (Basic) | $2.88$1.80 | +60.0% |
| EPS (Diluted) | $2.78$1.76 | +58.0% |
| Shares Outstanding (Basic) | 271.57M290.03M | −6.4% |
| Shares Outstanding (Diluted) | 281.86M296.13M | −4.8% |
05—Questions
Frequently Asked Questions
What drove the increase in net product revenues in 2025?
The filing attributes the 17% increase in net product revenues, to $2,122.8 million, primarily to a 16% increase in CABOMETYX units sold, reflecting demand for CABOMETYX with nivolumab as first-line treatment of advanced RCC and for previously treated advanced NET, plus a 1% increase in average net selling price. Gross product revenues rose 20%, partly offset by higher discounts and allowances, which increased 25% to $889.0 million.
Why did collaboration revenues decline in 2025?
Collaboration revenues fell to $197.3 million from $359.3 million. The filing says milestone revenues were $14.3 million in 2025 versus $169.3 million in 2024, when Ipsen achieved a $600.0 million cumulative net sales milestone that generated $150.0 million of license revenue. Development cost reimbursements also fell to $3.7 million from $25.8 million.
What are the key regulatory catalysts for zanzalintinib?
Exelixis submitted an NDA in December 2025 for zanzalintinib with atezolizumab in previously treated metastatic CRC based on the STELLAR-303 trial. The FDA accepted it with standard review and a PDUFA target action date of December 3, 2026. The STELLAR-303 dual primary endpoint of OS in patients without liver metastases is expected in mid-2026, and STELLAR-304 top-line results are expected in mid-2026.
What generic competition risks does CABOMETYX face?
Several companies have filed ANDAs or 505(b)(2) applications referencing CABOMETYX. The filing says MSN, Azurity and Handa are involved in patent litigation or challenges, and Sun settled in December 2025. The consolidated litigation is set for trial on November 2, 2026. The composition-of-matter patent, with patent term extension, expires in August 2026. The company says generic versions would likely decrease U.S. CABOMETYX revenues significantly.
How is the company using its cash?
The company repurchased $947.5 million of stock in cash during 2025, as shown in financing activities, with total repurchases of $962.0 million recorded in equity. Cash, cash equivalents and marketable securities declined to $1.66 billion from $1.75 billion. Management says the cash and revenue base will support operations for at least 12 months and beyond, and it expects 2026 R&D and SG&A spending to increase.
06—Continue